Biodesix completes enrollment of insight study assessing clinical utility of the veristrat® blood-based host immune classifier

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the large multi-center observational registry study insight (clinical effectiveness assessment of veristrat® testing and validation of immunotherapy tests in nsclc subjects) (nct03289780) has completed enrollment of 5,000 patients with non-small cell lung cancer (nsclc). the study was designed to further validate the utility of the.
BDSX Ratings Summary
BDSX Quant Ranking